Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;19(1):36-41.
doi: 10.5056/jnm.2013.19.1.36. Epub 2013 Jan 8.

Effects of ramosetron on gastrointestinal transit of Guinea pig

Yoo Mi Park  1 , Young Ju Lee, Young Ho Lee, Tae Il Kim, Hyojin Park
Affiliations

Effects of ramosetron on gastrointestinal transit of Guinea pig

Yoo Mi Park et al. J Neurogastroenterol Motil. 2013 Jan.

Erratum in

  • J Neurogastroenterol Motil. 2013;19(2):275

Abstract

Background/aims: A selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist, ramosetron, inhibits stress-induced abnormal defecation in animals and is currently used as a therapeutic drug for irritable bowel syndrome with diarrhea. The aim of this study is to investigate the effect of ramosetron on altered gastrointestinal (GI) transit.

Methods: Male guinea pigs weighing approximately 300 g were used. The effect of ramosetron was investigated on altered GI transit induced by thyrotropin-releasing hormone (TRH), 5-HT, or mustard oil (MO). GI transit was evaluated by the migration of charcoal mixture from the pylorus to the most distal point, and expressed as a percentage (%) of charcoal migration (cm) of the total length of total small intestine (cm).

Results: The average charcoal transit was 51.3 ± 20.1% in the control (vehicle) group, whereas in the ramosetron group charcoal moved 56.6 ± 21.9%, 46.9 ± 9.14% and 8.4 ± 5.6% of the total small intestine at the concentrations of 10, 30 and 100 µg/kg, respectively. GI transit after administration of TRH (100 µg/kg), 5-HT (10 mg/kg) or MO (10 mg/kg) was accelerated compared to vehicle (5-HT, 94.9 ± 9.22%; TRH, 73.4 ± 14.7%; MO, 81.0 ± 13.7%). Ramosetron inhibited GI transit altered by 5-HT, TRH or MO.

Conclusions: Ramosetron modulated GI transit. We suggest that ramosetron may be therapeutically useful for those with accelerated upper GI transit.

Keywords: Gastrointestinal transit; Mustard oil; Ramosetron; Serotonin 5-HT3 receptor antagonist; Thyrotropin-releasing hormone.

PubMed Disclaimer

Conflict of interest statement

Yoo Mi Park and Hyojin Park planned this study. Yoo Mi Park and Young Ju Lee was conducted the study. Young Ho Lee and Tae Il Kim contributed to revise and draft the manuscript. Yoo Mi Park wrote the paper.

Figures

Figure 1
Figure 1
The effect of ramosetron on gastrointestinal (GI) transit. Ramosetron inhibits GI transit. *P < 0.01 compared with the control group (n = 7).
Figure 2
Figure 2
The effect of ramosetron on altered gastrointestinal (GI) transit induced by 5-hydroxytryptamine (5-HT). The 5-HT accelerated GI charcoal transit dose-dependently. The maximum effect was observed at a dose of 10 mg/kg (*P < 0.01 compared with the control group [n = 7]). Ramosetron significantly inhibited the accelerated GI transit caused by 5-HT (**P < 0.01 compared with the 5-HT group [n = 6]).
Figure 3
Figure 3
The effect of ramosetron on altered gastrointestinal (GI) transit induced by thyrotropin-releasing hormone (TRH). TRH accelerated GI charcoal transit. The maximum effect was observed in TRH at a dose of 100 µg/kg (*P = 0.102 compared with the control group [n = 6]). Ramosetron significantly inhibited the accelerated GI transit caused by TRH (**P < 0.05 compared with the TRH group [n = 6]).
Figure 4
Figure 4
The effect of ramosetron on altered gastrointestinal (GI) transit induced by mustard oil (MO). MO accelerated GI charcoal transit. The maximum effect was observed in MO at a dose of 10 mg/kg (*P < 0.01 compared with the control group [n = 7]). Ramosetron significantly inhibited the accelerated GI transit caused by MO (**P < 0.01 compared with the MO group [n = 7]).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) 2002;38:75–89. - PubMed
    1. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992;67:732–738. - PubMed
    1. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:175–180. - PubMed
    1. Shafik A, El-Sibai O, Ahmed I. Parasympathetic extrinsic reflex: role in defecation mechanism. World J Surg. 2002;26:737–740. discussion 741. - PubMed
    1. Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20:557–565. - PubMed

LinkOut - more resources